Savara(US:SVRA) Businesswire·2025-10-30 18:56Core Points - Rosen Law Firm is reminding investors about a class action lawsuit filed on behalf of Savara Inc. (NASDAQ: SVRA) shareholders for the period between March 7, 2024, and May 23, 2025 [1][4] - The lawsuit alleges that Savara misled investors regarding its business operations, particularly concerning the Biologics License Application (BLA) for MOLBREEVI, a treatment for a rare lung disease [2][3] Allegations - The lawsuit claims that Savara's BLA for MOLBREEVI lacked sufficient information on its chemistry, manufacturing, and controls, making FDA approval unlikely in its current form [3] - It is alleged that Savara would not complete the BLA submission within the previously represented timeframe, increasing the likelihood of needing additional capital [3] - The public statements made by Savara were claimed to be materially false and misleading, resulting in investor damages when the true details emerged [3] Legal Proceedings - Investors interested in serving as lead plaintiffs must file motions with the court by November 7, 2025 [4] - Participation in the case is not required to be eligible for recovery, allowing investors to remain absent class members if they choose [4] Rosen Law Firm Overview - Rosen Law Firm specializes in shareholder rights litigation and has recovered over $1 billion for shareholders since its inception [6]